Home > Journals > Otorinolaringologia > Past Issues > Otorinolaringologia 2020 September;70(3) > Otorinolaringologia 2020 September;70(3):95-100

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

CASE REPORT   

Otorinolaringologia 2020 September;70(3):95-100

DOI: 10.23736/S0392-6621.19.02263-X

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Simultaneous medication-related osteonecrosis of the jaw and maxillo-mandibular localization of multiple myeloma

Stefano FRANCHI, Matteo BRUCOLI, Paolo BOFFANO , Arnaldo BENECH

Division of Maxillofacial Surgery, University of Eastern Piedmont, Novara, Italy



Bone resorption inhibitors, such as bisphosphonates (BPs) and denosumab (DB), are widely used for the treatment of bone disease in patients with multiple myeloma (MM) and metastatic cancer. These antiresorptive therapies however increase the risk of developing medication-related osteonecrosis of the jaw (MRONJ), whose diagnosis is based on both clinical signs, such as exposed necrotic bone, purulent drainage and pathologic fracture, and radiographic findings, such as structural alteration of the bone, erosion and sequestrum. While localization of MM at the jaw is a rare sign of presentation, it is quite commonly found in the advanced disease. Of note, the simultaneous finding of MM and MRONJ at the same site has been rarely reported. Here, we present a case of advanced MM in an 82-year-old man with a history of BP administration presenting with MRONJ characterized by mandibular pathological fracture and maxillary bone exposure, positive for myeloma plasma cells on histopathological examination.


KEY WORDS: Osteonecrosis; Jaw; Multiple myeloma; Surgery; Disease management

top of page